Selected research
Industry Growth & Trends
Global Neuroendocrine Carcinoma Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Neuroendocrine Carcinoma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Neuroendocrine Carcinoma market include Teva, Novartis, Pfizer, Abbvie, Valeant, Mateon, Lexicon, Jubilant and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Neuroendocrine Carcinoma market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Neuroendocrine Carcinoma market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuroendocrine Carcinoma market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuroendocrine Carcinoma.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Neuroendocrine Carcinoma market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Neuroendocrine Carcinoma Market by Company
Teva
Novartis
Pfizer
Abbvie
Valeant
Mateon
Lexicon
Jubilant
Ipsen
F.Hoffmann-La Roche
Chiasma
Advanced Accelerator
Neuroendocrine Carcinoma Segment by Type
Somatostatin Analogs
Chemotherapy
Targeted Therapy
Neuroendocrine Carcinoma Segment by Application
Oncology Centres
Clinics
Hospital
Ambulatory Surgery Centres
Neuroendocrine Carcinoma Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Neuroendocrine Carcinoma companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Somatostatin Analogs
- Chemotherapy
- Targeted Therapy
Applications
- Oncology Centres
- Clinics
- Hospital
- Ambulatory Surgery Centres
Companies covered
- Teva
- Novartis
- Pfizer
- Abbvie
- Valeant
- Mateon
- Lexicon
- Jubilant
- Ipsen
- F.Hoffmann-La Roche
- Chiasma
- Advanced Accelerator
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Neuroendocrine Carcinoma Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Neuroendocrine Carcinoma Market Size by Region (2021-2032)
- 1.4.1 Global Neuroendocrine Carcinoma Market Size by Region (2021-2026)
- 1.4.2 Global Neuroendocrine Carcinoma Market Size by Region (2027-2032)
- 1.5 Key Regions Neuroendocrine Carcinoma Market Size (2021-2032)
- 1.5.1 North America Neuroendocrine Carcinoma Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Neuroendocrine Carcinoma Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Growth Rate (2021-2032)
- 1.5.4 South America Neuroendocrine Carcinoma Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Neuroendocrine Carcinoma Market Size Growth Rate (2021-2032)
2 Neuroendocrine Carcinoma Market by Type
- 2.1 Type Introduction
- 2.1.1 Somatostatin Analogs
- 2.1.2 Chemotherapy
- 2.1.3 Targeted Therapy
- 2.2 Global Neuroendocrine Carcinoma Market Size by Type
- 2.2.1 Global Neuroendocrine Carcinoma Market Size Overview by Type (2021-2032)
- 2.2.2 Global Neuroendocrine Carcinoma Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Neuroendocrine Carcinoma Market Size Forecasted by Type (2027-2032)
- 2.3 Global Neuroendocrine Carcinoma Market Size by Regions
- 2.3.1 North America Neuroendocrine Carcinoma Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Neuroendocrine Carcinoma Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Neuroendocrine Carcinoma Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Neuroendocrine Carcinoma Market Size Breakdown by Type (2021-2026)
3 Neuroendocrine Carcinoma Market by Application
- 3.1 Type Introduction
- 3.1.1 Oncology Centres
- 3.1.2 Clinics
- 3.1.3 Hospital
- 3.1.4 Ambulatory Surgery Centres
- 3.2 Global Neuroendocrine Carcinoma Market Size by Application
- 3.2.1 Global Neuroendocrine Carcinoma Market Size Overview by Application (2021-2032)
- 3.2.2 Global Neuroendocrine Carcinoma Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Neuroendocrine Carcinoma Market Size Forecasted by Application (2027-2032)
- 3.3 Global Neuroendocrine Carcinoma Market Size by Regions
- 3.3.1 North America Neuroendocrine Carcinoma Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Neuroendocrine Carcinoma Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Neuroendocrine Carcinoma Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Neuroendocrine Carcinoma Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Neuroendocrine Carcinoma Industry Trends
- 4.2 Neuroendocrine Carcinoma Industry Drivers
- 4.3 Neuroendocrine Carcinoma Industry Opportunities and Challenges
- 4.4 Neuroendocrine Carcinoma Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Neuroendocrine Carcinoma Revenue (2021-2026)
- 5.2 Global Neuroendocrine Carcinoma Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Neuroendocrine Carcinoma Key Company Headquarters & Area Served
- 5.4 Global Neuroendocrine Carcinoma Company, Product Type & Application
- 5.5 Global Neuroendocrine Carcinoma Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Neuroendocrine Carcinoma Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Neuroendocrine Carcinoma Players Market Share by Revenue in 2025
- 5.6.3 2025 Neuroendocrine Carcinoma Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva
- 6.1.1 Teva Company Information
- 6.1.2 Teva Business Overview
- 6.1.3 Teva Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Neuroendocrine Carcinoma Product Portfolio
- 6.1.5 Teva Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Company Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis Neuroendocrine Carcinoma Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Pfizer Neuroendocrine Carcinoma Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 Abbvie
- 6.4.1 Abbvie Company Information
- 6.4.2 Abbvie Business Overview
- 6.4.3 Abbvie Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Abbvie Neuroendocrine Carcinoma Product Portfolio
- 6.4.5 Abbvie Recent Developments
- 6.5 Valeant
- 6.5.1 Valeant Company Information
- 6.5.2 Valeant Business Overview
- 6.5.3 Valeant Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Valeant Neuroendocrine Carcinoma Product Portfolio
- 6.5.5 Valeant Recent Developments
- 6.6 Mateon
- 6.6.1 Mateon Company Information
- 6.6.2 Mateon Business Overview
- 6.6.3 Mateon Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Mateon Neuroendocrine Carcinoma Product Portfolio
- 6.6.5 Mateon Recent Developments
- 6.7 Lexicon
- 6.7.1 Lexicon Company Information
- 6.7.2 Lexicon Business Overview
- 6.7.3 Lexicon Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Lexicon Neuroendocrine Carcinoma Product Portfolio
- 6.7.5 Lexicon Recent Developments
- 6.8 Jubilant
- 6.8.1 Jubilant Company Information
- 6.8.2 Jubilant Business Overview
- 6.8.3 Jubilant Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Jubilant Neuroendocrine Carcinoma Product Portfolio
- 6.8.5 Jubilant Recent Developments
- 6.9 Ipsen
- 6.9.1 Ipsen Company Information
- 6.9.2 Ipsen Business Overview
- 6.9.3 Ipsen Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Ipsen Neuroendocrine Carcinoma Product Portfolio
- 6.9.5 Ipsen Recent Developments
- 6.10 F.Hoffmann-La Roche
- 6.10.1 F.Hoffmann-La Roche Company Information
- 6.10.2 F.Hoffmann-La Roche Business Overview
- 6.10.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio
- 6.10.5 F.Hoffmann-La Roche Recent Developments
- 6.11 Chiasma
- 6.11.1 Chiasma Company Information
- 6.11.2 Chiasma Business Overview
- 6.11.3 Chiasma Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Chiasma Neuroendocrine Carcinoma Product Portfolio
- 6.11.5 Chiasma Recent Developments
- 6.12 Advanced Accelerator
- 6.12.1 Advanced Accelerator Company Information
- 6.12.2 Advanced Accelerator Business Overview
- 6.12.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio
- 6.12.5 Advanced Accelerator Recent Developments
7 North America
- 7.1 North America Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 7.3 North America Neuroendocrine Carcinoma Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 8.3 Europe Neuroendocrine Carcinoma Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Neuroendocrine Carcinoma Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 10.3 South America Neuroendocrine Carcinoma Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Neuroendocrine Carcinoma Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst